Download fulltext
HTML
Abbasi, F., Davar, R., Shamsi, F., & Dashti, S. (2023). Insulin-like growth factor-1 on cycle day 2 and assisted reproductive techniques outcome: A cross-sectional study. International Journal of Reproductive BioMedicine (IJRM), 21(2), 139–146. https://doi.org/10.18502/ijrm.v21i2.12804
https://doi.org/10.18502/ijrm.v21i2.12804
statistics
- 177 Abstract Views
- 132 PDF Views
- 0 HTML Views
authors
-
Fariba Abbasi
Fariba Abbasi
Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
-
Robab Davar
Robab Davar
Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
-
Farimah Shamsi
Farimah Shamsi
Center for Healthcare Data Modeling, Department of Biostatistics and Epidemiology, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
-
Saeideh Dashti
Saeideh Dashti
Research and Clinical Center for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Published Date
- Mar 9, 2023
Insulin-like growth factor-1 on cycle day 2 and assisted reproductive techniques outcome: A cross-sectional study
Abstract
Background: Individualized assisted reproductive techniques (ART) can improve ART outcomes. Some studies suggested using insulin-like growth factor-1 (IGF-1) level on cycle day 2 for individualized ART.
Objectives: To investigate the relationship between the serum levels of IGF-1 on day 2 of the cycle and ART outcomes.
Materials and Methods: In this cross-sectional study, cycle day 2 serum levels of IGF- 1 were measured in 175 women aged between 18-44 yr as candidates for in vitro fertilization or intracytoplasmic sperm injection. All participants received antagonist protocol, and the relationship between serum levels of IGF-1 and ART outcomes according to the number of oocytes were investigated; poor responders (oocytes < 5), normal responders (oocytes 5-15), and hyper responders (oocytes > 15). Results: Poor responders had higher serum level of IGF-1 when compared with normal and hyper-responders; however, this difference was not statistically significant (p = 0.41). The serum levels of IGF-1 in women with zero retrieved oocytes and those cycles that were canceled for the inappropriate ovarian response were not significantly different compared to other women in the group of poor responders. An inverse relationship was observed between the serum level of IGF-1 and anti-Mullerian hormone levels. Furthermore, no significant relationship between serum level of IGF-1 with age, body mass index, number of 2 pronucleus, and number of embryos was observed.
Conclusions: According to our results, the serum levels of IGF-1 may not be able to predict ART outcomes. It seems necessary to conduct more studies with larger sample size in this field.
Key words: Insulin-like growth factor-1, Poor ovarian response, Oocyte retrieval, Assisted reproductive technique outcome.
References
[1] Hugh ST, Lubna P, Emre S. Speroff’s Clinical gynecologic endocrinology and infertility. Philadelphia: Wolters Kluwer; 2020.
[2] Maged AM, Ragab MA, Shohayeb A, Saber W, Ekladious Sh, Hussein EA, et al. Comparative study between single versus dual trigger for poor responders in GnRHantagonist ICSI cycles: A randomized controlled study. Int J Gynecol Obstet 2020; 152: 395–400.
[3] Allahbadia GN, Ata B, Lindheim SR, Woodward BJ, Bhagavath B. Textbook of assisted reproduction. Singapore: Springer; 2020.
[4] Pellicer A, Lightman A, Diamond MP, Russel JB, DeCherney AH. Outcome of in vitro fertilization in women with low response to ovarian stimulation. Fertil Steril 1987; 47: 812–815.
[5] Patel NH, Esteves SC. Advances in assisted reproductive technology. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2020.
[6] Salahuddin H, Anjum N, Rehman R, Rehman S, Kumar W, Jan NA. The role of IGF-I in females selected for assisted reproductive technique (Art). Annals Abbasi Shaheed Hospital and Karachi Medical and Dental College 2020; 25: 3–9.
[7] Man L, Lekovich J, Canon Ch, Rosenwaks Z, James D. Cycle day 2 insulin-like growth factor-1 serum levels as a prognostic tool to predict controlled ovarian hyperstimulation outcomes in poor respondes. Fertil Steril 2020; 113: 1205–1214.
[8] Johnson NP, Bagrie EM, Coomarasamy A, Bhattacharya S, Shelling AN, Jessop S, et al. Ovarian reserve tests for predicting fertility outcomes for assisted reproductive technology: The International Systematic Collaboration of Ovarian Reserve Evaluation protocol for a systematic review of ovarian reserve test accuracy. BJOG 2006; 113: 1472–1480.
[9] Mousavi Fatemi H, Lawrenz B. Individualized in-vitro fertilization. UK: Cambridge University Press; 2021.
[10] Dosouto C, Calaf J, Polo A, Haahr Th, Humaidan P. Growth hormone and reproduction: Lessons learned from animal models and clinical trials. Front Endocrinol 2019; 10: 404.
[11] Laron Z. Somatomedin-1 (recombinant insulin-like growth factor-1): Clinical pharmacology and potential treatment of endocrine and metabolic disorders. Bio Drugs 1999; 11: 55–70.
[12] Dag ZO, Dilbaz B. Impact of obesity on infertility in women. J Turk Ger Gynecol Assoc 2015; 16: 111–117.
[13] Hsu CJ, Hammond JM. Concomitant effects of growth hormone on secretion of insulin-like growth factor I and progesterone by cultured porcine granulosa cells. Endocrinology 1987; 121: 1343–1348.
[14] Committee Opinion No. 589. Female age-related fertility decline. Fertil Steril 2014; 101: 633–634.
[15] Adashi EY, Resnick CE, Hurwitz A, Ricciarelli E, Hernandez ER, Roberts CT, et al. Insulin-like growth factors: The ovarian connection. Hum Reprod 1991; 6: 1213–1219.
[16] Stadtmauer L, Vidali A, Lindheim SR, Sauer MV. Follicular fluid insulin-like growth factor-I and insulin-like growth factor-binding protein-1 and -3 vary as a function of ovarian reserve and ovarian stimulation. J Assist Reprod Genet 1998; 15: 587–593.
[17] Baumgarten SC, Convissar SM, Fierro MA, Winston NJ, Scoccia B, Stocco C. IGF1R signaling is necessary for FSHinduced activation of AKT and differentiation of human Cumulus granulosa cells. J Clin Endocrinol Metab 2014; 99: 2995–3004.
[18] Stocco C, Baumgarten SC, Armouti M, Fierro MA, Winston NJ, Scoccia B, et al. Genome-wide interactions between FSH and insulin-like growth factors in the regulation of human granulosa cell differentiation. Hum Reprod 2017; 32: 905–914.
[19] Kolibianakis EM, Venetis CA, Diedrich K, Tarlatzis BC, Griesinger G. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: A systematic review and meta-analysis. Hum Reprod Update 2009; 15: 613–622.
[20] Kucuk T, Kozinoglu H, Kaba A. Growth hormone cotreatment within a GnRH agonist long protocol in patients with poor ovarian response: A prospective, randomized, clinical trial. J Assist Reprod Genet 2008; 25: 123–127.
[21] Mehta BN, Chimote NM, Chimote MN, Chimote NN, Nath NM. Follicular fluid insulin like growth factor-1 (FF IGF-1) is a biochemical marker of embryo quality and implantation rates in in vitro fertilization cycles. J Hum Reprod Sci 2013; 6: 140–146.
[22] Man L, Chen Y, Li N, Luo Y, Pan X, Zhou Sh. Level of IGF1 in follicular fluid associated with IVF pregnancy outcome in the application of growth hormone. Ginekologia Polska 2022; in press.
[23] Lekovich J, Man L, Canon C, Pereira N, James D. Cycle day 2 Igf-1 levels are predictive of negative pregnancy outcome in poor responders. Fertil Steril 2017; 108: e217– e218.
[24] Sehat B, Andersson S, Vasilcanu R, Girnita L, Larsson O. Role of ubiquitination in IGF-1 receptor signaling and degradation. PLoS One 2007; 2: e340.
[25] Yovich JL, Zaidi S, Nguyen MDK, Hinchliffe PM. Measuring IGF-1 and IGFBP-3 profiles in women seeking assisted reproduction: Relationship to ovarian reserve parameters, namely AFC and AMH (study 2). GSC Biol Pharm Sci 2020; 13: 035–053.
[26] Yovich JL, Zaidi S, Nguyen MDK, Hinchliffe PM. Measuring IGF-1 and IGFBP-3 Profiles in women seeking assisted reproduction: Relationship to clinical parameters (study 1). J Pers Med 2020; 10: 122.
[27] Rao KA. Principles and practice of assisted reproductive technology. 2nd Ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2019.
[28] Weissman A, Gardner DK, Shoham Z, Howles CM. Textbook of assisted reproductive techniques. 5th Ed. Boca Raton: CRC Press; 2018.
[29] Bachelot A, Monget P, Imbert-Bollore P, Coshigano K, Kopchick JJ, Kelly PA, et al. Growth hormone is required for ovarian follicular growth. Endocrinology 2002; 143: 4104– 4112.
[30] Yovich JL, Zaidi S, Nguyen MDK, Hinchliffe PM. Measuring IGF-1 and IGFBP-3 profiles in women seeking assisted reproduction: Relationship to serum growth hormone levels (Study 3). GSC Biol Pharm Sci 2020; 13: 032-053.
[31] Zhang Sh, Tang Y, Wang X, Zong Y, Li X, Cai S, et al. Estrogen valerate pretreatment with the antagonist protocol does not increase oocyte retrieval in patients with low ovarian response: A randomized controlled trial. Hum Reprod 2022; 37: 1431-1439.
[2] Maged AM, Ragab MA, Shohayeb A, Saber W, Ekladious Sh, Hussein EA, et al. Comparative study between single versus dual trigger for poor responders in GnRHantagonist ICSI cycles: A randomized controlled study. Int J Gynecol Obstet 2020; 152: 395–400.
[3] Allahbadia GN, Ata B, Lindheim SR, Woodward BJ, Bhagavath B. Textbook of assisted reproduction. Singapore: Springer; 2020.
[4] Pellicer A, Lightman A, Diamond MP, Russel JB, DeCherney AH. Outcome of in vitro fertilization in women with low response to ovarian stimulation. Fertil Steril 1987; 47: 812–815.
[5] Patel NH, Esteves SC. Advances in assisted reproductive technology. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2020.
[6] Salahuddin H, Anjum N, Rehman R, Rehman S, Kumar W, Jan NA. The role of IGF-I in females selected for assisted reproductive technique (Art). Annals Abbasi Shaheed Hospital and Karachi Medical and Dental College 2020; 25: 3–9.
[7] Man L, Lekovich J, Canon Ch, Rosenwaks Z, James D. Cycle day 2 insulin-like growth factor-1 serum levels as a prognostic tool to predict controlled ovarian hyperstimulation outcomes in poor respondes. Fertil Steril 2020; 113: 1205–1214.
[8] Johnson NP, Bagrie EM, Coomarasamy A, Bhattacharya S, Shelling AN, Jessop S, et al. Ovarian reserve tests for predicting fertility outcomes for assisted reproductive technology: The International Systematic Collaboration of Ovarian Reserve Evaluation protocol for a systematic review of ovarian reserve test accuracy. BJOG 2006; 113: 1472–1480.
[9] Mousavi Fatemi H, Lawrenz B. Individualized in-vitro fertilization. UK: Cambridge University Press; 2021.
[10] Dosouto C, Calaf J, Polo A, Haahr Th, Humaidan P. Growth hormone and reproduction: Lessons learned from animal models and clinical trials. Front Endocrinol 2019; 10: 404.
[11] Laron Z. Somatomedin-1 (recombinant insulin-like growth factor-1): Clinical pharmacology and potential treatment of endocrine and metabolic disorders. Bio Drugs 1999; 11: 55–70.
[12] Dag ZO, Dilbaz B. Impact of obesity on infertility in women. J Turk Ger Gynecol Assoc 2015; 16: 111–117.
[13] Hsu CJ, Hammond JM. Concomitant effects of growth hormone on secretion of insulin-like growth factor I and progesterone by cultured porcine granulosa cells. Endocrinology 1987; 121: 1343–1348.
[14] Committee Opinion No. 589. Female age-related fertility decline. Fertil Steril 2014; 101: 633–634.
[15] Adashi EY, Resnick CE, Hurwitz A, Ricciarelli E, Hernandez ER, Roberts CT, et al. Insulin-like growth factors: The ovarian connection. Hum Reprod 1991; 6: 1213–1219.
[16] Stadtmauer L, Vidali A, Lindheim SR, Sauer MV. Follicular fluid insulin-like growth factor-I and insulin-like growth factor-binding protein-1 and -3 vary as a function of ovarian reserve and ovarian stimulation. J Assist Reprod Genet 1998; 15: 587–593.
[17] Baumgarten SC, Convissar SM, Fierro MA, Winston NJ, Scoccia B, Stocco C. IGF1R signaling is necessary for FSHinduced activation of AKT and differentiation of human Cumulus granulosa cells. J Clin Endocrinol Metab 2014; 99: 2995–3004.
[18] Stocco C, Baumgarten SC, Armouti M, Fierro MA, Winston NJ, Scoccia B, et al. Genome-wide interactions between FSH and insulin-like growth factors in the regulation of human granulosa cell differentiation. Hum Reprod 2017; 32: 905–914.
[19] Kolibianakis EM, Venetis CA, Diedrich K, Tarlatzis BC, Griesinger G. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: A systematic review and meta-analysis. Hum Reprod Update 2009; 15: 613–622.
[20] Kucuk T, Kozinoglu H, Kaba A. Growth hormone cotreatment within a GnRH agonist long protocol in patients with poor ovarian response: A prospective, randomized, clinical trial. J Assist Reprod Genet 2008; 25: 123–127.
[21] Mehta BN, Chimote NM, Chimote MN, Chimote NN, Nath NM. Follicular fluid insulin like growth factor-1 (FF IGF-1) is a biochemical marker of embryo quality and implantation rates in in vitro fertilization cycles. J Hum Reprod Sci 2013; 6: 140–146.
[22] Man L, Chen Y, Li N, Luo Y, Pan X, Zhou Sh. Level of IGF1 in follicular fluid associated with IVF pregnancy outcome in the application of growth hormone. Ginekologia Polska 2022; in press.
[23] Lekovich J, Man L, Canon C, Pereira N, James D. Cycle day 2 Igf-1 levels are predictive of negative pregnancy outcome in poor responders. Fertil Steril 2017; 108: e217– e218.
[24] Sehat B, Andersson S, Vasilcanu R, Girnita L, Larsson O. Role of ubiquitination in IGF-1 receptor signaling and degradation. PLoS One 2007; 2: e340.
[25] Yovich JL, Zaidi S, Nguyen MDK, Hinchliffe PM. Measuring IGF-1 and IGFBP-3 profiles in women seeking assisted reproduction: Relationship to ovarian reserve parameters, namely AFC and AMH (study 2). GSC Biol Pharm Sci 2020; 13: 035–053.
[26] Yovich JL, Zaidi S, Nguyen MDK, Hinchliffe PM. Measuring IGF-1 and IGFBP-3 Profiles in women seeking assisted reproduction: Relationship to clinical parameters (study 1). J Pers Med 2020; 10: 122.
[27] Rao KA. Principles and practice of assisted reproductive technology. 2nd Ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2019.
[28] Weissman A, Gardner DK, Shoham Z, Howles CM. Textbook of assisted reproductive techniques. 5th Ed. Boca Raton: CRC Press; 2018.
[29] Bachelot A, Monget P, Imbert-Bollore P, Coshigano K, Kopchick JJ, Kelly PA, et al. Growth hormone is required for ovarian follicular growth. Endocrinology 2002; 143: 4104– 4112.
[30] Yovich JL, Zaidi S, Nguyen MDK, Hinchliffe PM. Measuring IGF-1 and IGFBP-3 profiles in women seeking assisted reproduction: Relationship to serum growth hormone levels (Study 3). GSC Biol Pharm Sci 2020; 13: 032-053.
[31] Zhang Sh, Tang Y, Wang X, Zong Y, Li X, Cai S, et al. Estrogen valerate pretreatment with the antagonist protocol does not increase oocyte retrieval in patients with low ovarian response: A randomized controlled trial. Hum Reprod 2022; 37: 1431-1439.